{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:46:39Z","timestamp":1776872799409,"version":"3.51.2"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (MDA5-DM) is an autoimmune disease, characterized by a particular skin ulcer and rapidly progressive interstitial lung disease (RP-ILD). This case highlights diagnostic challenges of this disease and underscores the importance of early recognition and timely intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 59-year-old woman presented to the hospital with systemic myalgia, fatigue, and anorexia. Following admission she developed recurrent fever. Computed tomography of the chest and bronchoalveolar lavage fluid analysis revealed severe pulmonary infections. Despite 2 weeks of antimicrobial therapy yielding radiographic improvement, her dermatomyositis symptoms worsened.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Immune profiling and myositis-specific antibody testing confirmed the diagnosis of MDA5-DM-ILD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The following treatment included methylprednisolone combined with immunosuppressants (tofacitinib, tacrolimus, tocilizumab, mycophenolate mofetil). Subsequent computed tomography imaging demonstrated cavity lesions and micronodules, with lung biopsy confirming fungal and viral coinfections. Therapy was adjusted to sustained methylprednisolone (22\u2009mg\/d), tacrolimus (0.5\u2009g\/d), targeted antimicrobials (ganciclovir, voriconazole) and prophylactic use of sulfamethoxazole complex.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>At discharge, the patient achieved clinical stability with resolved fever, normalized oxygen saturation and improved myalgia, though mild epigastric discomfort persisted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>MDA5-DM-ILD poses challenges for clinicians due to its diagnostic difficulty, rapid progression and secondary infection risks. Early immunosuppression combined with infection prevention is the key to a successful treatment of this disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042536","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:01:02Z","timestamp":1748318462000},"page":"e42536","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2328-6955","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongji","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhui","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Deparment of Internal Medicine, Qingdao Public Health Clinical Center, Qingdao, Shandong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-2503","authenticated-orcid":false,"given":"Wenqing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250527","first-page":"99","article-title":"Dermatomiositis anti-MDA5. Revisi\u00f3n de la literatura [Anti-MDA5 dermatomyositis. Literature review].","volume":"61","author":"Castro-Molina","year":"2023","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies.","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","article-title":"Clinical spectrum and therapeutics in Canadian patients with anti-melanoma diferentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review (in eng).","volume":"39","author":"Huang","year":"2019","journal-title":"Rheumatol Int"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"103420","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u03b3: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies.","volume":"22","author":"Thuner","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"105136","DOI":"10.1016\/j.ebiom.2024.105136","article-title":"MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C).","volume":"104","author":"David","year":"2024","journal-title":"EBioMedicine"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00296-022-05149-6","article-title":"Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.","volume":"42","author":"Gonzalez","year":"2022","journal-title":"Rheumatol Int"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","article-title":"High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis.","volume":"62","author":"Chen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-024-03382-x","article-title":"Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy.","volume":"26","author":"Weng","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"R10-20250527","first-page":"70","article-title":"Effect of anti-RO-52 antibody on rapid progression of interstitial lung disease and prognosis in patients with melanin-differentiation related gene-5 antibody positive dermatomyositis.","volume":"30","author":"Kang","year":"2022","journal-title":"J Pract Cardio Cerebral Pulm Vasc Dis"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation associated gene 5-positive dermatomyositis.","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/1346-8138.13659","article-title":"Potential inhibition of development of rapidly progressive interstitial lung disease by prompt and sufficient immunosuppressive treatment in patients with anti melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.","volume":"44","author":"Shu","year":"2017","journal-title":"J Dermatol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14397595.2020.1740400","article-title":"Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age.","volume":"31","author":"Yamaguchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti\u2010melanoma differentiation\u2010associated 5 gene antibody\u2010positive dermatomyositis.","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:01:05Z","timestamp":1748318465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":15,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042536","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}